OLMA heads into the autumn with one of the most heavily shorted profiles in clinical-stage biotech and a stock that has lost nearly 5% in a week, testing bulls whose conviction rests entirely on a single Phase 3 readout that won't arrive until next year.
Short interest at 20.3% of the free float is the defining feature of this setup, and it has been sticky. Shares short have risen roughly 5.6% over the past month, pulling back only slightly in the most recent session to around 15.95 million shares. Days to cover, per FINRA's fortnightly data, run at 18.5 — a meaningful drag in a name where any adverse update could see sellers move quickly. The ORTEX short score is running at 72.1, near the top of the range it has held for the past two weeks, which reflects the combined weight of elevated SI, the borrow profile, and recent price weakness. One notable counterpoint: the lending market is not tight. Availability has actually loosened over the week, moving to roughly 359% — meaning there are more than three shares sitting in the lending pool for every one already borrowed. That is a normal-to-loose reading. Borrow cost at 0.51% is cheap. New shorts can enter without fighting over inventory. That structural ease in the borrow market suggests the current short position is a fundamental view on the pipeline, not a technical squeeze waiting to unwind.
Options traders broadly agree with the bears, though the signal is calmer than it appears at first glance. The put/call ratio is 1.81, right on its 20-day average of 1.82 — a z-score essentially at zero. The ratio has been drifting lower from a peak above 2.0 in late July, which could reflect put positions rolling off rather than any fresh appetite for upside calls. There is no unusual positioning event here, just a persistently defensive baseline.
The Street remains formally bullish but has been trimming conviction. JP Morgan's Anupam Rama cut his target from $52 to $46 after the August print, maintaining Overweight. Citigroup trimmed from $62 to $59, also staying at Buy. HC Wainwright came in at $36, down from $38. These are all August actions — within the 30-day window — and they all point in the same direction: positive ratings intact but price targets coming in as the clock ticks on OPERA-01. The consensus mean target is $39.30 against a close of $10.22, a gap so wide it reflects not conviction but the structural math of biotech — the binary between a successful Phase 3 and a complete reset. Goldman Sachs carries a $27 target at Buy, having already cut sharply from $38 back in March; that lower anchor is arguably the most calibrated view on near-term risk.
The institutional register shows FMR (Fidelity) as the largest holder at 13.9%, adding 1.76 million shares in the most recent reported period. BlackRock added 1.06 million shares, reaching 7.7% of shares. Both moves are from the passive-to-active spectrum and represent meaningful conviction adds into weakness. However, Cormorant Asset Management — typically a sophisticated healthcare specialist — cut its position by 1.75 million shares to 2.15 million, and Bain Capital Life Sciences trimmed as well. The divergence between index-adjacent buyers and specialist sellers is worth tracking. On the activist register, Logos Global Management filed a 13D/A last May, disclosing a stake then at 4.7% — below the 5% threshold. As required by disclosure rules, positions near that level may shift without a further filing, so the current Logos stake should be treated as indicative rather than precise.
The earnings history adds another layer of caution. The two most recent quarterly reports each produced double-digit declines: -12.6% on the session after the August 11 print, and -13.4% the day before for a separately timed release. The one bright spot was a June 17 data presentation that produced a 3.5% gain on the day and a 21% rally over the following week — a reminder that it is clinical news, not financial results, that moves OLMA. Next earnings is scheduled for November 9. The data event that matters — the OPERA-01 Phase 3 readout — is still guided for first half 2027. Everything between now and then is positioning around a binary.
With short interest entrenched, borrow loose, and the Street watching for any update on palazestrant's path through the trial, the next material catalyst for OLMA is a clinical communications event, not a financial one — making pipeline newsflow the only variable worth monitoring between now and year-end.
See the live data behind this article on ORTEX.
Open OLMA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
